Payment overview · 2025
General Payments
$899.70
47 reported records · 11 companies
Healthcare provider profile · identity verified
Mikhail Radivilov, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKELAND, FL · NPI 1720050966
Verified facts
What the public records show
CMS Open Payments records show Mikhail Radivilov, MD received $899.70 in general payments during 2025 across 47 reported records.
PFIZER INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $221.28 | 24.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $175.29 | 19.5% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $172.97 | 19.2% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.74 | 11.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.58 | 8.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.59 | 6.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.65 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.48 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.83 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.42 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.87 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $867.43 | 46 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $221.28 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $221.28 | 11 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $172.97 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.84 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $102.74 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.45 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
91 | 91 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
48 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 735 | 214 |
| Atorvastatin Calcium | Atorvastatin Calcium | 693 | 199 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 531 | 169 |
| Lisinopril | Lisinopril | 530 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 122 |
| Losartan Potassium | Losartan Potassium | 380 | 115 |
| Trazodone Hcl | Trazodone Hcl | 263 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 228 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 71 |
| Alprazolam | Alprazolam | 185 | 63 |
| Omeprazole | Omeprazole | 184 | 59 |
| Sertraline Hcl | Sertraline Hcl | 183 | 61 |
| Simvastatin | Simvastatin | 178 | 52 |
| Lovastatin | Lovastatin | 176 | 49 |
| Furosemide | Furosemide | 173 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 51 |
| Gabapentin | Gabapentin | 167 | 54 |
| Eliquis | Apixaban | 159 | 35 |
| Atenolol | Atenolol | 155 | 49 |
| Terazosin Hcl | Terazosin Hcl | 142 | 40 |
| Carvedilol | Carvedilol | 141 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 45 |
| Allopurinol | Allopurinol | 129 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 127 | 34 |
| Ozempic | Semaglutide | 123 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 31 |
| Metformin Hcl | Metformin Hcl | 104 | 39 |
| Ezetimibe | Ezetimibe | 99 | 32 |
| Montelukast Sodium | Montelukast Sodium | 99 | 30 |
| Irbesartan | Irbesartan | 98 | 30 |
| Donepezil Hcl | Donepezil Hcl | 96 | 26 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 91 | 91 |
| Finasteride | Finasteride | 90 | 26 |
| Potassium Chloride | Potassium Chloride | 80 | 29 |
| Synthroid | Levothyroxine Sodium | 69 | 17 |
| Jardiance | Empagliflozin | 68 | 16 |
| Mounjaro | Tirzepatide | 66 | 17 |
| Rybelsus | Semaglutide | 66 | 18 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 65 | 65 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 18 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 62 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 18 |
| Meloxicam | Meloxicam | 61 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 14 |
| Azithromycin | Azithromycin | 51 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 48 | 32 |
| Farxiga | Dapagliflozin Propanediol | 47 | 12 |
| Propranolol Hcl | Propranolol Hcl | 45 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 16 |
| Memantine Hcl | Memantine Hcl | 41 | 11 |
| Diazepam | Diazepam | 40 | 12 |
| Clonazepam | Clonazepam | 39 | 11 |
| Jantoven | Warfarin Sodium | 39 | 12 |
| Methylprednisolone | Methylprednisolone | 37 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Famotidine | Famotidine | 36 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 36 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 15 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | 11 |
| Lactulose | Lactulose | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Prednisone | Prednisone | 32 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 28 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | 13 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 15 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 11 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Byetta | Exenatide | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $899.70 · 47 records | PFIZER INC. | Auvelity, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, LEQVIO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error